THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.16]-CMP163 ID: TIP-MED-000433 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Isoxsuprine Hydrochloride IP

Active Ingredient / Scientific Identity: Isoxsuprine Hydrochloride IP • Class: Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher & Antiarrhythmic (Physiological Calcium Antagonist & NMDA Blocker)

⚖️ Compare Profile
Generic / Entity NameIsoxsuprine Hydrochloride IP ([12.16]-CMP163)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassParenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher & Antiarrhythmic (Physiolo
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Isoxsuprine Hydrochloride IP (TIP-MED-000433, Reference Code [12.16]-CMP163) is classified under Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher & Antiarrhythmic (Physiological Calcium Antagonist & NMDA Blocker). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-04 (Option 4A; from displaced HTML [12.18]). Beta-agonist uterine relaxant comparison note.
Co-indexed per approved Author Decision DEC-04 (Option 4A; from displaced HTML [12.18]). Beta-agonist uterine relaxant comparison note.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-04 (Option 4A; from displaced HTML [12.18]). Beta-agonist uterine relaxant comparison note.

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and control of seizures in severe pre-eclampsia and eclampsia (Pritchard / Zuspan regimens)
  • Torsades de Pointes polymorphic VT
  • acute severe life-threatening asthma refractory to bronchodilators
  • severe hypomagnesaemia

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-04 (Option 4A; from displaced HTML [12.18]). Beta-agonist uterine relaxant comparison note.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.16].
Metabolism & Biotransformation:
Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.
Elimination & Renal Adjustment:
Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.
Hepatic Impairment Considerations:
Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Myasthenia gravis; heart block or severe myocardial damage; anuria (for maintenance doses). • Precautions: HIGH-ALERT OBSTETRIC ELECTROLYTE: Therapeutic eclampsia serum Mg2+ = 2.0–3.5 mmol/L (4–7 mEq/L); Loss of patellar knee-jerk reflex occurs at >3.5–5.0 mmol/L (8–10 mEq/L); Respiratory paralysis at >5.0–6.5 mmol/L (12 mEq/L); Cardiac arrest at >10–12.5 mmol/L (25 mEq/L). Always keep CALCIUM GLUCONATE 10% (10 mL = 1 g IV over 3-5 min) at the bedside as the immediate physiological antidote!

Key Clinical Precautions: Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Flushing, intense warmth, sweating, pain at IM site, nausea.
  • Loss of deep tendon reflexes, respiratory depression/apnoea, hypotension, bradycardia, heart block, cardiac arrest.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Nifedipine / Calcium channel blockers -> additive hypotension and neuromuscular weakness; Neuromuscular blockers (Vecuronium, Rocuronium, Succinylcholine) -> markedly prolonged paralysis; Aminoglycosides -> additive neuromuscular blockade

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.16].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Inform patient that a strong wave of body heat and flushing during the IV injection is normal; report difficulty breathing or extreme weakness immediately.
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Injection: 50% w/v (500 mg/mL = ~2 mmol Mg2+/mL) in 2 mL (1 g) and 10 mL (5 g) ampoules.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.